SurGraft TL® represents a state-of-the-art triple-layer amnion-derived allograft meticulously designed for wound coverage, serving as a protective barrier and facilitating advanced wound care.
SurGraft TL® is processed in compliance with the United States Food and Drug Administration current Good Tissue Practices (cGTP) Regulations and the American Association of Tissue Banks Standards. We pride ourselves on quality and testing that meet or exceed industry standards.
SurGraft TL® has been shown to be effective as a protective covering in the management of chronic non-healing ulcers including diabetic, pressure, and venous ulcers.
SurGraft TL® is regulated under Section 361 of the PHS Act and 21 CFR Part 1271 and is intended for homologous use.
HCPCS Level II Code Q4263, "SurGraft TL, per square centimeter"
Human Extracellular Matrix (ECM)
The membrane sheet provides a protective covering that may aid in wound management.
Immunogenicity
The amniotic membrane has unique non-immunological properties.
Barrier
The extracellular matrix acts as a barrier and may potentiate the migration and adhesion of resident cells.
Growth Factors
The membrane is a natural source of cytokines and growth factors.
